ALZHEIMER'S ANTIBODY

Delivering Personalised Drugs to transform Neuroscience in the 21st century

Date:	7 April , 2010
Venue:	Radisson BLU Royal Viking Hotel
City:	Stockholm, Sweden

In the Chair:

Dr. Christer Köhler Head of Global Discovery Research

ASTRAZENECA

In your eminent Speaker panel:

Dr. Kenneth Rhodes, Vice President Discovery Neurobiology

BIOGEN IDEC (USA)

Dr. Hansruedi Loetscher, Head of Molecular Neuroscience in CNS Discovery

F. HOFFMANN-LA ROCHE AG

Professor Lars Lannfelt Chairman of the Board, Founder

BIOARCTIC NEUROSCIENCE AB

Dr. Andreas Muhs, Chief Scientific Officer

AC IMMUNE SA

Dr. Pieter Jelle Visser, Representative, Research Neurodegenerative Diseases

THE JOINT PROGRAMMING INITIATIVE

Professor Bengt Winblad, Department of Neurobiology, Care Sciences and Society

KAROLINSKA INSTITUTE

Professor Dr. Roger Nitsch, Director of the Division of

Psychiatry Research

UNIVERSITY OF ZURICH

Event Summary:

Alzheimer’s antibody represents the next promising field in the Life Science Industry. Across the globe, pharmaceutical and biotechnology companies collaborate with universities to be the pioneers delivering Alzheimer’s antibody therapeutics to activate the body’s own immune response against mild to moderate Alzheimer’s disease.

To fully capitalise on the potential of Alzheimer’s antibody, scientists focus on how to combine antibody therapy with personalised medicine to increase the number of tailored drugs and diagnostics in order to successfully prevent dementia in a growing population. By identifying the right patient groups amongst a younger population it is possible to use Alzheimer’s antibody therapeutics to optimise the level of antibodies in the blood to lower a person’s risk of developing Alzheimer’s and other disorders of the brain.

This Executive Life Science Industry event presents the leaders of Alzheimer disease providing your R & D organisation with a platform to discover ground breaking therapeutics and diagnostic tools within Alzheimer’s antibody. Our distinguished speaker panel will share first hand experiences to successfully design Alzheimer’s antibody programmes enabling your company to be a front runner in Neuroscience.

This event will tackle key issues such as:

Diversifying clinical studies in Phase II and Phase III to increase the number of personalised Alzheimer’s antibody drugs and diagnostics
Creating a pipeline in neuroscience to meet the increasing demand for tailored Alzheimer’s and dementia therapeutics
Motivating family and friends with dementia to support better health and dignity for the elderly in a modern society
Delivering a customised Alzheimer’s antibody therapy to match medical treatment to your personal genetic make up
How do you exploit personalised medicine to develop tailored medical dementia treatments for a growing population?
Who owns the data and how do you share intellectual property?
Pioneering neuroscience through co-operation in the Life Science Industry
Examining current status and future initiatives to support inter-disciplinary R & D projects within neurodegenerative diseases
Establishing partnerships in the Life Science Industry to meet a global demand for new and better medicines in neuroscience
Designing human monoclonal antibody-based drug discovery approach to develop preventive new treatments for Alzheimer’s disease

Target audience and Job titles:

Presidents, Chief Executive Officers, Chief Scientific Officers, Vice Presidents, Directors and Heads within: